RareResearch.AI
← Back to atlas

G831A

Category 3/4 — Most DruggableUncertain significanceLumenal · predictedσ-1 candidateSource card
GlycineAlanine at position 831 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type G831 — hydrogen bond to L833
Fullscreen ↗
DynaMut2 mutant · G831A
Mutant A831 — energy-minimized; local contact network preserved
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost0 gained3 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondL833L833Preserved
Polar contactL833L833Preserved
Van der WaalsL833L833Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.15kcal/mol
Destabilising — mild
AlphaMissense
0.886
likely pathogenic
AlphaFold pLDDT
78
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, single submitter
Associated conditions
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.2492G>C
ClinVar accessionVCV002734649
Last evaluated2023/08/27 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Full Variant Card

WFS1 Wolframin — G831A Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Glycine → Alanine at position 831. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.886, DynaMut2 ΔΔG -0.15 kcal/mol (destabilising).


Identity

FieldValue
VariantG831A (p.Glycine831Alanine)
DNA changec.2492G>C
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV002734649
Amino acid changeGlycine (G) → Alanine (A)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 83178.12 — well-folded
DomainC-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position contextC-terminal lumenal domain · position 831 projects into the ER lumen
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 831 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is small/flexible (glycine — backbone flexibility, no sidechain); the mutant is small/hydrophobic (alanine — methyl sidechain). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.8862
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.15 (Destabilising)
Job ID178092109859
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092109859

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, single submitter
Last evaluated2023/08/27 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeG831A is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)


Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.15 < 2 kcal/mol (fold intact) + AlphaMissense 0.886 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.15 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.886. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • G831A_molstar_viewer.html — interactive 3D viewer (auto-highlights position 831 with ball-and-stick + neighbors within 5Å)
  • G831A_variant_card.md — this card (source of truth)
  • G831A_variant_card.html — styled printable card
  • G831A_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • G831A_wildtype_interactions.pse / G831A_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the G831A PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download G831A PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.